INTRODUCTION
CHEMORESSA 250MG TABLET contains Gefitinib which belongs to the group of medicines called Antineoplastics. It is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have activating mutation of the EGFR-TK.
It is generally characterized by symptoms such as chest pain?or discomfort, persistent cough, trouble breathing, wheezing, tiredness and difficulty while swallowing which may be diagnosed as any of its type as adenocarcinoma (cancer involving the outer part of the lung), squamous cell carcinoma (cancer occurring in the centre part of the lungs), and large cell carcinoma (cancer that can occur in any part of the lung).
Along with this treatment, your doctor might ask you to take liver function test to assess your liver function.
CHEMORESSA 250MG TABLET is not recommended for use in patients allergic to Gefitinib. Before taking CHEMORESSA 250MG TABLET, inform your doctor if you have other lung problems, liver, or kidney problems.
CHEMORESSA 250MG TABLET is not recommended for use in pregnant and breastfeeding women. It is not recommended for use in children and adolescents (below 18 years). Consult your doctor before taking CHEMORESSA 250MG TABLET.
The most common side effects of taking CHEMORESSA 250MG TABLET are diarrhoea, vomiting, nausea, skin reactions, loss of appetite, weakness, and red or sore mouth. Consult with your doctor if any of the symptoms worsen.
USES OF CHEMORESSA 250MG TABLET

Used to treat adults with non-small cell lung cancer

HOW CHEMORESSA 250MG TABLET WORKS
CHEMORESSA 250MG TABLET works by decreasing the survival rate and proliferation of malignant cancer cells in lung tissues by blocking a protein called epidermal growth factor receptor (EGFR) which is responsible for the growth and spread of cancer cell thereby preventing the growth and spread of cancer cells to other parts of the body.
DIRECTIONS FOR USE
Take CHEMORESSA 250MG TABLET as advised by your physician. Swallow the medicine with a glass of water. Do not crush or chew the medicine. Your doctor will decide the correct dose and duration of CHEMORESSA 250MG TABLET for you depending upon your age, body weight and disease condition.
SIDE EFFECTS OF CHEMORESSA 250MG TABLET

COMMON

Diarrhoea

Vomiting

Nausea

Skin reactions (acne-like rash)

Loss of appetite

Weakness

Red or sore and dry mouth

Dry, red, or itchy eyes

Red and sore eyelids

Nail problems

Hair loss

Fever

Bleeding such as nosebleed or blood in urine

Signs of cystitis such as burning sensations while urinating, urgent need to urinate

UNCOMMON

Signs of inflamed pancreas such as very severe pain in the upper part of the abdomen, severe nausea and vomiting

Signs of inflammation of the liver such as general feeling of being unwell, with or without possible jaundice (yellowing of the skin and eyes).

Signs of gastrointestinal perforation such as severe stomach pain, chills, fever

Signs of palmar-plantar erythrodysaesthesia syndrome or hand and foot syndrome such as skin reaction on the palms of the hands and soles of the feet with tingling, numbness, swelling, redness, or pain

RARE

Signs of inflammation of the blood vessels in the skin such as bruising or patches of non-blanching rash on the skin

Signs of haemorrhagic cystitis (inflammatory condition of urinary bladder) such as burning sensation while urinating, urgent need to urinate along with blood in the urine
Stop taking CHEMORESSA 250MG TABLET and contact your doctor immediately if you experience any of the following side effects:
Signs of allergic reaction such as swollen face, lips, tongue or throat, red and itchy skin, nettle rash and difficulty breathing and difficulty in swallowing

Signs of interstitial lung disease (inflammation and scarring of lung disease) such as serious breathlessness, or sudden worsening of breathlessness possibly with a cough or fever

Dehydration due to long term or severe diarrhoea, vomiting, nausea, or loss of appetite

Signs of an ulcer on the surface of the eye (cornea) such as pain, redness, watery eyes, light sensitivity, changes in vision or ingrowing eyelashes

HOW TO MANAGE SIDE EFFECTS
Nausea or Vomiting:
Stick to simple meals. Avoid eating oily, fried, and spicy foods. Do not perform any strenuous activities immediately after eating. Consult your doctor if the symptom did not improve.
Constipation:
Eat plenty of fiber rich foods such as vegetables, fresh fruits, and cereals and drink plenty of water while taking CHEMORESSA 250MG TABLET. Exercise more regularly. Consult your doctor if the symptom did not improve.
Diarrhea:
Drink a lot of fluids, such as water, squash, or fruit juice to keep yourself hydrated. Do not take any medicine on your own for treating diarrhea without consulting your doctor.
WARNING & PRECAUTIONS

PREGNANCY
CHEMORESSA 250MG TABLET is not recommended for use in pregnant women as it may harm the baby. Consult your doctor before taking CHEMORESSA 250MG TABLET.
BREASTFEEDING
CHEMORESSA 250MG TABLET is not recommended for use in breastfeeding women as it is unsafe to the baby. Consult your doctor before taking CHEMORESSA 250MG TABLET.
DRIVING AND USING MACHINES
If you feel weak while taking CHEMORESSA 250MG TABLET, consult your doctor before driving or using tools or machines.
ALCOHOL
Avoid consumption of alcohol while taking CHEMORESSA 250MG TABLET since it may increase the risk of liver damage.
KIDNEY
CHEMORESSA 250MG TABLET should be used with caution in patients having kidney problems. Consult your doctor before taking CHEMORESSA 250MG TABLET.
LIVER
CHEMORESSA 250MG TABLET should be used with caution in patients having liver problems. Consult your doctor before taking CHEMORESSA 250MG TABLET.
ALLERGY
Do not take CHEMORESSA 250MG TABLET if you are allergic to Gefitinib or to any other ingredients of this medicine.
LUNGS
CHEMORESSA 250MG TABLET should be used with caution in patients having other lung disease. Consult your doctor before taking CHEMORESSA 250MG TABLET.
OTHERS
Use in pediatrics:
CHEMORESSA 250MG TABLET is not recommended for use in children and adolescents (below 18 years). Consult your doctor before taking CHEMORESSA 250MG TABLET.
Use in geriatrics:
CHEMORESSA 250MG TABLET should be used with caution in elderly patients (aged 65 years and above). Consult your doctor before taking CHEMORESSA 250MG TABLET.
INTERACTIONS
A. Drug ? Drug Interactions:
Before taking CHEMORESSA 250MG TABLET, inform your doctor if you are taking any of the following medicines:
Medicines used in the treatment of epilepsy (Ex. phenytoin, carbamazepine)

Medicines used in the treatment of tuberculosis (Ex. rifampicin)

Medicines used in the treatment of fungal infection (Ex. itraconazole)

Medicines used in the treatment of sleeping disorders (Ex. barbiturates such as phenobarbital)

Medicines used to prevent blood clots (Ex. warfarin)

Medicines used in the treatment of ulcers, indigestion, heartburn and to reduce acids in the stomach such as proton-pump inhibitors (Ex. lansoprazole, omeprazole, aluminium hydroxide, magnesium carbonate, cimetidine, famotidine)

St. John?s wort (herbal remedy used for depression and anxiety)
Overdosage:
If you or anyone else accidentally takes too much of CHEMORESSA 250MG TABLET, consult your doctor immediately or visit the nearby hospital.
SYNOPSIS

Drug :?? Gefitinib

Pharmacological Category :?? Antineoplastic agents

Therapeutic Indication :?? Non-small cell lung cancer

Dosage Forms :?? Tablet

MORE INFORMATION

Keep CHEMORESSA 250MG TABLET out of reach of children

Store at room temperature

FAQs ABOUT CHEMORESSA 250MG TABLET
What is CHEMORESSA 250MG TABLET and why is it given?
CHEMORESSA 250MG TABLET contains Gefitinib which belongs to the group of medicines called as Antineoplastic agents. It is used in adults to treat non-small cell lung cancer in which malignant cells form in the lung tissue.
What are the most common side effects of CHEMORESSA 250MG TABLET?
The most common side effects of taking CHEMORESSA 250MG TABLET are diarrhoea, vomiting, nausea, skin reactions, loss of appetite, weakness, and red or sore mouth. Consult with your doctor if any of the symptoms worsen.
Can CHEMORESSA 250MG TABLET be used in children?
No. CHEMORESSA 250MG TABLET is not recommended for use in children and adolescents (below 18 years). If CHEMORESSA 250MG TABLET is accidentally ingested by a child or adolescent, go to the hospital immediately and consult the doctor for further management.
Is CHEMORESSA 250MG TABLET safe for pregnant and breast-feeding women?
CHEMORESSA 250MG TABLET is not recommended for use in pregnant and breast-feeding women since it might cause harm to the foetus and nursing child. Consult your doctor before taking CHEMORESSA 250MG TABLET.
REFERENCES
1. KD. Tripathi. Anticancer Drugs. Essentials of medical pharmacology. Seventh edition. 2013. Page ? 870.
2. Gefitinib. NIH National Library of Medicine, National center for biotechnology information. Pubchem. [Revised in June 2022] [Accessed on 15th June 2022] https://pubchem.ncbi.nlm.nih.gov/compound/Gefitinib#section=Mechanism-of-Action
3. Yasoo Sugiura, Etsuo Nemoto,?Osamu Kawai,Yasuyuki Ohkubo,?Hisae Fusegawa,?and?Shizuka Kaseda. Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy. NIH National Library of Medicine, National center for biotechnology information. PMC PubMed Central. June 2013. [Accessed on 15th June 2022] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217440/
4. Cipla (EU) Limited. Electronic Medicines Compendium (EMC). [Revised in May 2022] [Accessed on 15th June 2022] https://www.medicines.org.uk/emc/files/pil.10456.pdf
5. AstraZeneca Pharmaceuticals LP Wilmington. U.S. Food & Drug Administration. [Revised in August 2018] [Accessed on 15th June 2022] https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021688s017lbl.pdf
USEFUL DIAGNOSTIC TESTS

Liver function test

CT Scan

PET Scan

Complete Blood Count (CBC)

PRODUCT DETAILS

Net Qty

1 N

Item Weight

17.5 g

Ingredient

GEFITINIB 250MG

Hsn Code

30049049

Show more

Only logged in customers who have purchased this product may leave a review.

Reviews

There are no reviews yet.